Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly.
In order to ascertain if pirenzepine (Pz), an antimuscarinic drug, could inhibit GH secretion in acromegaly, 8 patients were submitted to 3 successive treatment courses of 9 days each: Pz, bromocriptine (BRC) and Pz plus BRC. No change in basal levels of GH after Pz administration was seen, but its reduction (p less than 0.05) by BRC was observed. Pz plus BRC did not improve this response. None of these drugs abolished the paradoxical GH response to TRH. In 7 normal controls, Pz suppressed the GH responsiveness to GHRH (p less than 0.001), but not in acromegalic patients. BRC, instead, blunted this response. In conclusion, cholinergic control of GH secretion is altered in acromegaly. Pz, either when administered alone or associated with BRC, is not useful for the treatment of this disease.
Fiszlejder
L
L
Department of Endocrinology, Hospital C. Durand, Buenos Aires, Argentina.
Penacini
O
O
Ratz
S
S
Storani
M
M
Oneto
A
A
Guitelman
A
A
D000172:Acromegaly / Q000188:drug therapy / Q000503:physiopathology*; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013973:Thyrotropin-Releasing Hormone
D001971:Bromocriptine; D010890:Pirenzepine; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone